NHL Clinical Trial
Official title:
Influence of Corn Farming on the Immune System
Verified date | September 2020 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will look for links between corn farming practices and short-term changes in
immune function in farmers throughout the growing season. It will examine biologic effects
associated with specific pesticide exposures and general planting activities, such as
tillage. Farmers have an increased risk of non-Hodgkin s lymphoma and certain other blood
cancers such as multiple myeloma and leukemia, but the reasons for this increase have not
been identified. Findings of this study may contribute to learning the causes of cancers such
as non-Hodgkin s lymphoma.
Farmers enrolled in the Agricultural Health Study (a study of pesticide applicators and their
spouses in Iowa and North Carolina) and a group of control subjects selected from
agricultural extension workers in Iowa may participate in this study.
The study involves six home visits to farmers and four visits to farmers to individuals in
the control group. All participants will complete the following tests and procedures:
- Questionnaires and diaries During the first visit, all participants will have a medical
history review, including questions about smoking and other health habits. Farmers will
be asked about their farming practices, and controls will be asked about their
occupations. Farmers will fill out daily diaries during short time periods of interest
around certain pesticide applications to describe farming activities that day. At other
times during the growing season before harvest, farmers will fill out weekly diaries
describing farming activities; controls, meanwhile, will fill out weekly diaries
describing their health and work activities. At home visits during the farmers growing
season, all participants will fill out questionnaires about their health. Finally,
farmers and controls will complete a more extensive questionnaire in the off-season,
during the last home visit, to learn about their activities and exposures in the final
part of the year (post-harvest for farmers).
- Urine samples: At the time of each home visit, controls will provide a urine sample that
the interviewer will take that day. Farmers, too, will provide urine samples at the time
of home visits, but they will also collect urine samples for a period of 4 days each
during short time periods of interest after certain pesticide applications. The
interviewer will collect these samples immediately at the end of these periods.
- Blood samples: At the time of each home visit, the interviewer will draw 50 ml (3.5
tablespoons) of blood.
- Telephone calls: Farmers will be called frequently from once every 2 weeks to every
other day to schedule visits at the times of interest. Control subjects will also be
called frequently to schedule their visits closely to those of the farmers.
Status | Completed |
Enrollment | 40 |
Est. completion date | February 5, 2008 |
Est. primary completion date | January 31, 2004 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 100 Years |
Eligibility |
- INCLUSION CRITERIA: Male corm farmers in the AHS who plan to apply specific pesticides. Any ethnicity or race groups are included. Limit the age criteria for inclusion to 40 to 60 years. Only non-smokers are included in the study. |
Country | Name | City | State |
---|---|---|---|
United States | University of Iowa | Iowa City | Iowa |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Immunilogical effects of farming exposues | Evaluate the changes in immune parameters in farmers throughout the growing season, as well as effects of specific pesticide exposures including atrazine and organophosphate (OP) insecticides. Pesticide exposures (e.g., atrazine, OPs, and potentially 2,4-D or carbamates) are being assessed primarily by measurement of the parent compound or its metabolites in urine, and additional information on farming activities and work practices will be obtained by questionnaire. Farmers serve as their own self-controls, and a selected control group will provide a means for external comparison. | Before and after application of pesticies |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04555811 -
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
|
Phase 1 | |
Completed |
NCT00333190 -
CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation
|
N/A | |
Recruiting |
NCT03535753 -
Safety and Efficacy Evaluation of Decitabine With R-GDP
|
Phase 1 | |
Recruiting |
NCT06119685 -
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
|
Phase 1/Phase 2 | |
Completed |
NCT00513175 -
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia
|
N/A | |
Recruiting |
NCT05641428 -
Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL
|
Phase 2 | |
Active, not recruiting |
NCT05879744 -
A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
|
Phase 1 | |
Withdrawn |
NCT01101581 -
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04139252 -
A National Study for Blood Based Response Monitoring of B-cell Lymphoma Patients
|
||
Recruiting |
NCT04440436 -
Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients
|
Phase 1/Phase 2 | |
Terminated |
NCT04840784 -
First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML
|
Phase 1 | |
Recruiting |
NCT05665062 -
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
|
Phase 1 | |
Terminated |
NCT02702492 -
PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)
|
Phase 1 | |
Completed |
NCT03527147 -
Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)
|
Phase 1 | |
Withdrawn |
NCT05365100 -
A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL
|
Phase 1/Phase 2 | |
Terminated |
NCT00814983 -
Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02847949 -
A Study of IGN002 for Refractory NHL
|
Phase 1 | |
Completed |
NCT00891592 -
Umbilical Cord Blood Transplant for Hematological Malignancies
|
Phase 1 | |
Completed |
NCT00546793 -
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
|
Phase 1/Phase 2 | |
Recruiting |
NCT03739502 -
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
|
Phase 2 |